Search research articles
Contact Us
Filters
Showing results (31-40 of 122) with videos related to
Page
of 13
Sort By:
Annals of Hematology
|
December 14, 2019
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Massimo Breccia, Claudia Baratè, Giulia Benevolo, et al.
Clinical Lymphoma & Myeloma
|
May 2, 2009
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results
Antonio Palumbo, Patrizia Falco, Antonietta Falcone, et al.
European Journal of Neurology
|
September 9, 2022
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up
Mattia Parisi, Irene Dogliotti, Michele Clerico, et al.
Annals of Hematology
|
June 16, 2019
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis
Massimo Breccia, Luigiana Luciano, Novella Pugliese, et al.
The Lancet. Haematology
|
September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Claire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Haematologica
|
February 9, 2019
Once-weekly <i>versus</i> twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, et al.
Leukemia
|
May 28, 2025
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea
Francesca Palandri, Massimo Breccia, Elena M Elli, et al.
Blood
|
May 29, 2008
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo, Sara Bringhen, Anna M Liberati, et al.
Annals of Hematology
|
January 15, 2026
Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study
Fabrizio Cavalca, Roberto Latagliata, Novella Pugliese, et al.
Seminars in Hematology
|
May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria
Steven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Page
of 13
Search research articles
Search
Showing results (31-40 of 122) with videos related to
Sort By:
Page
of 13
Annals of Hematology
|
December 14, 2019
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Massimo Breccia, Claudia Baratè, Giulia Benevolo, et al.
Clinical Lymphoma & Myeloma
|
May 2, 2009
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results
Antonio Palumbo, Patrizia Falco, Antonietta Falcone, et al.
European Journal of Neurology
|
September 9, 2022
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up
Mattia Parisi, Irene Dogliotti, Michele Clerico, et al.
Annals of Hematology
|
June 16, 2019
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis
Massimo Breccia, Luigiana Luciano, Novella Pugliese, et al.
The Lancet. Haematology
|
September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Claire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Haematologica
|
February 9, 2019
Once-weekly <i>versus</i> twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, et al.
Leukemia
|
May 28, 2025
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea
Francesca Palandri, Massimo Breccia, Elena M Elli, et al.
Blood
|
May 29, 2008
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo, Sara Bringhen, Anna M Liberati, et al.
Annals of Hematology
|
January 15, 2026
Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study
Fabrizio Cavalca, Roberto Latagliata, Novella Pugliese, et al.
Seminars in Hematology
|
May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria
Steven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Page
of 13